The European Medicines Agency (EMA) has announced its approval of two new biosimilar medications, Afqlir and Opuviz, to treat age-related macular degeneration (ARMD). The active ingredient of both agents is aflibercept, already used in the similar medication Eylea, authorized in 2012. At a meeting of the Committee for Medicinal Products for Human Use (CHMP…
